All the results show that individuals with the C allele of FGFR1 rs2420946 presented a greater risk of overall toxicity for CET chemotherapy in breast cancer (adjusted OR = 1.65, 95% CI = 1.11–2.46, P = 0.013). This evidence concerns the gene FGFR1 and breast cancer.